Byung Hee Jeon

Title: Byung Hee Jeon: Innovator in Cancer Screening Technologies

Introduction

Byung Hee Jeon is a prominent inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of cancer diagnostics, holding a total of seven patents. His innovative approaches focus on improving the accuracy and efficiency of cancer patient screening methods.

Latest Patents

Among his latest patents is the "Androgen receptor variant-based prostate cancer patient screening method." This method analyzes whether androgen receptor-targeted therapy is applicable to prostate cancer patients through optical image analysis of circulating tumor cells and an androgen receptor variant. Another notable patent is the "EML4-ALK gene mutation analysis method," which involves qRT-PCR primers capable of detecting the EML4-ALK gene variant based on circulating tumor cells. This method offers a more sensitive detection limit than conventional methods and provides a lung cancer patient screening method that can detect the EML4-ALK gene variant even when solid lung cancer tissue samples are difficult to collect.

Career Highlights

Throughout his career, Byung Hee Jeon has worked with notable companies such as Cytogen Co., Ltd. and Cytogen Corporation. His work has significantly advanced the field of cancer diagnostics, particularly in the areas of prostate and lung cancer.

Collaborations

Byung Hee Jeon has collaborated with various professionals in his field, including Jong Kil Lee, to further enhance the development of innovative cancer screening technologies.

Conclusion

Byung Hee Jeon's contributions to cancer diagnostics through his patents and collaborations highlight his role as a leading inventor in this critical area of healthcare. His work continues to pave the way for more effective cancer screening methods, ultimately benefiting patients worldwide.